- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01480986
IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC
May 17, 2015 updated by: Shen Lin, Peking University
a Prospective Study on the Efficacy and Safety Using Sequential Therapy of Irinotecan Combined With Cisplatin (IP)and Octretide Lar in the First Line Treatment of Metastatic or Inoperable Gastrointestinal Poorly Differentiated Neuroendocrine Carcinoma: the IPO-NEC Trial
This is a prospective, single-armed, open label study on the efficacy and safety of sequential IP therapy(Irinotecan plus cisplatin) and octreotide lar in the treatment of GI poorly diffrentiated Neuroendocrine carcinoma.
Patient with written consents will enter the phase one step of the trial, receiving IP therpy.
Once the IP therapy has been finished without disease progression or progression occurs during the treatment, the patient will enter the phase two step of the trial, receiving octreotide treatment.
The primary endpoint is progression free survival in the two steps respectively and secondary endpoint is disease control rate, overall survival and safety
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Beijing Tumor Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written Informed consent
- Male or female patients >=18 years old
- Histologically or cytologically confirmed poorly differentiated neuroendocrine carcinoma originating from the GI tract. The grade of the disease is grade 2 or grade 3
- No previous treatment is allowed including chemotherapy, radiotherapy,immunotherapy or others. In case the patient received adjuvant therapy after surgery, enrollment is allowed if the adjuvant therapy doesn't contain cisplatin or irinotican and at the same time, the last day of chemotherapy is ≥180 days before screening.
- Target lesion more than 1cm in diameter by enhanced CT or MRI 21 days before enrollment
- The laboratory parameter meets the following criteria 7 days before enrollment
- Hemoglobin ≥90g/L
- Absolute neutrophil count≥1.5×10^9/L, platelets 100×10^9/L;
- ALT and AST≤2.5 ULN(in case of the patients with liver metastasis,ALT and AST≤5.0 ULN)
- ALP ≤2.5 ULN (in case of the patients with liver metastasis,≤5.0 ULN)
- Total Serum bilirubin ≤1.5 ULN
- Serum creatinine ≤1.0 ULN
- KPS ≥70
- Estimated survival ≥90 days
- Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of enrollment and must be willing to use adequate methods of contraception during the study and for 30 days after last study durg administration.
Exclusion Criteria:
- Known sensitivity to 5-HT3 antagonist and hypersensitivity to the other treatment agents including irinotecan, cisplatin and octreotide lar
- Any participation in trials simultaneously or 4 weeks before screening.
- Undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such surgery.
- Uncontrolled severe diarrhea
- Unconrolled active infection (fever ≥38 degrees due to infection)
- severe hepatopathy including active hepatitis and hepatic cirrhosis, renal dysfunction, severe pulmonary diseases including interstitial pneumonia, pulmonary fibrosis and severe pulmonary emphysema, uncontrolled diabetes, hypertension and other chronic systematic diseases.
- Chronic treatment with steroids.(In case of the patients with short-term use of steroids, the enrollment is permitted if the administration is stopped 2 weeks before screening.)
- confirmed or suspected CNS metastasis
- the history of peripheral nervous system impairment, obvious mental disorder or CNS impairment
- clinically significant heart disease, including congestive heart failure, symptomatic coronal heart disease, arrythmia uncontrolled by medication and acute myocardial infarction or cardiac insufficiency within 6 months before screening
- pregnant women or women in lactation period
- Fertile male or women of child-bearing potential refuse to take highly effective methods of birth control
- Incidence of other second primary malignant tumors, except for cured basal cell carcinoma and cervical carcinoma in situ.
- patients of legal incapacity or who have the potential of influence the whole trial due to medical or ethic reasons.
- Other patients who are not eligible to the trial under investigators' discretion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment arm
This is a single arm trial.
The patient will enter phase one and will continue to phase two once the disease progresses in phase one or the phase one has been completed.
|
Phase 1 irinotecan 180mg/m^2,ivgtt,90min,D1 Cisplatin 50 mg/m^2,ivgtt,120min,D1(with hydration) Phase 2 Octreotide 0.1mg,ih,q8h,D1-14 Octreotide lar 20mg,deep i.m,D8,
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival for Irinotecan plus cisplatin and octreotide
Time Frame: 2 years
|
The primary objective is to investigate the overall progression free suvival for irinotecan plus cisplatin and octretide.
The respective PFS of the two treatment steps will also be investigated.
The result will be compared with the history treatment outcomes for patients of poorly differentiated neuroendocrine carcinoma.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate
Time Frame: 2 years
|
The second objective includes the disease control rate of irinotecan plus cisplatin and octretide theray.
|
2 years
|
Overall survival
Time Frame: 3 years
|
The secondary objective includes the investigation of the overall survival for the patients receiving the sequential treatment of irinotecan plus cisplatin and octretide.
|
3 years
|
Safety
Time Frame: 3 years
|
The secondary objective also includes the investigation on the safety profiles of the two interventions, irinotecan plus cisplatin treatment and octretide.
The safety profile will be described using incidence of AEs and SAEs, using CTCAE criteria
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
September 1, 2012
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
November 25, 2011
First Submitted That Met QC Criteria
November 25, 2011
First Posted (Estimate)
November 29, 2011
Study Record Updates
Last Update Posted (Estimate)
May 19, 2015
Last Update Submitted That Met QC Criteria
May 17, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BJT-NEC-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Progression Free Survival of the Treatment
-
The First Affiliated Hospital of Xiamen UniversityNot yet recruitingProgression-free Survival;Progression-free Survival;Disease Control Rate; SafetyChina
-
Grupo Hospital de MadridCompletedProgression Free SurvivalSpain
-
Laibin People's HospitalCompletedThe Primary Study Metric is Progression-free Survival (PFS)
-
Peking Union Medical College HospitalOrigiMedRecruitingQuality of Life | Objective Response Rate | Overall Survival | Progression-free Survival | Disease Control Rate | Duration of Response | Five-year Survival RateChina
-
AstraZenecaCompletedProgression-free SurvivalKorea, Republic of
-
Qinghai Red Cross HospitalRecruitingAdvanced Cancer | Progression Free Survival | OlanzapineChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingProgression Free Survival(PFS)
-
Peking University People's HospitalXijing Hospital; Peking Union Medical College Hospital; Chinese PLA General Hospital and other collaboratorsWithdrawnToxicity | Overall Survival | Progression-free SurvivalChina
-
Zhejiang Cancer HospitalNot yet recruitingProgression-free Survival
-
Osijek University HospitalCompletedMechanical Ventilation | Survival | Duration of TreatmentCroatia
Clinical Trials on Irinotecan combined with cisplatin, octreotide lar
-
Chengfeng WangUnknown
-
Fudan UniversityCompletedCisplatin | Adenoid Cystic CarcinomasChina
-
Fudan UniversityCompletedEsophageal Squamous Cell CarcinomaChina
-
Fudan UniversityRecruitingTriple-negative Breast CancerChina
-
University Medical Center GroningenNRG Oncology; Dutch Cancer SocietyRecruitingVulvar Cancer | Sentinel Lymph Node | Lymph Node MetastasesUnited States, Netherlands
-
Shanghai 10th People's HospitalNot yet recruitingPolycystic Ovary Syndrome
-
National University Hospital, SingaporeRecruitingCancer | Liver DysfunctionSingapore
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Fudan UniversityUnknownEsophageal Squamous Cell CarcinomaChina
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingResectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaChina